Regeneron Genetics Center

Regeneron Genetics Center (RGC) is a wholly-owned subsidiary of Regeneron (Nasdaq: REGN) and also a unique integrated research initiative aimed at improving patient care by accelerating drug discovery and development through genomic approaches. Regeneron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic drug products for serious diseases. The company has candidate drugs in clinical trials for cancer, ophthalmic diseases, and inflammatory conditions, and is conducting preclinical programs in other areas.